Gilead Sciences, Inc. bought $20.1M of Assembly Biosciences (ASMB)
Executed Dec 19 2024, disclosed Dec 23 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 23 2024), the stock returned -5.3% (delay-adjusted); from the execution session (Dec 19 2024), -6.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Gilead Sciences, Inc. (10% owner) filed 4 Form 4 reports as a reporting entity in the past 24 months (4 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Assembly Biosciences, Inc. (ASMB). Across 4 priced purchase filings, the average 21-session return was +4.2% from execution and +0.5% from disclosure (delay-adjusted; derived). The largest single filing was $55.0M of ASMB (as filed), executed Aug 8 2025.
Healthcare · Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→as filed
Exec Aug 8 2025
Filed Oct 3 2025 · 4:30 PM ET †